Biotech

The Readout Meghana Keshavan

STAT Plus: Eli Lilly’s anti-vanity ad campaign for Oscars

Biotech Andrew Joseph

STAT Plus: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug

Biotech Adam Feuerstein

STAT Plus: In stunning outcome, Amylyx’s ALS drug fails large clinical trial

Matt's Take Matthew Herper

STAT Plus: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone

The Readout Damian Garde

STAT Plus: Banning WuXi is more complicated than it might sound

Biotech Allison DeAngelis

STAT Plus: Novo Nordisk’s obesity pill bests Wegovy in early trial

Biotech Adam Feuerstein

STAT Plus: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data

The Readout Damian Garde

STAT Plus: Bayer’s not breaking up. At least not yet

Biotech Allison DeAngelis

STAT Plus: Startup Alumis raises $259 million as it prepares for psoriasis trial

The Readout Damian Garde

STAT Plus: Where’s Lilly’s Alzheimer’s approval?

Biotech Jason Laughlin — Boston Globe

STAT Plus: ‘It’s a nightmare’: One of the most common children’s asthma meds is no longer available, leaving families scrambling

Biotech Robert Weisman — Boston Globe

STAT Plus: Massachusetts lawmakers consider $1 billion proposal to bolster region’s life science leadership

The Readout Meghana Keshavan

STAT Plus: Serum Institute of India wants government HPV contract

Biotech Adam Feuerstein

STAT Plus: Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows

The Readout Meghana Keshavan

STAT Plus: Despite good data, Ironwood’s shares plummet 

Exclusive Allison DeAngelis

STAT Plus: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships

Biotech Matthew Herper

STAT Plus: Here are the cancer drugs Pfizer thinks could reignite investors’ interest

Politics John Wilkerson

STAT Plus: What does America’s crackdown on Chinese firms mean for the U.S. biotech sector?

The Readout Damian Garde

STAT Plus: The next act for a biotech rainmaker

Biotech Matthew Herper

STAT Plus: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

Exclusive Allison DeAngelis

STAT Plus: Biotech launches with $82 million for Parkinson’s cell therapy

Biotech Allison DeAngelis

STAT Plus: Q&A: A biotech VC leader shares her next big bets

Pharma Matthew Herper

STAT Plus: Pfizer is about to make a big push in cancer. Will investors listen?

Adam's Take Adam Feuerstein

STAT Plus: An inside look at PIPEs, the financing trend that has biotech abuzz

The Readout Damian Garde

STAT Plus: Beam is trading like it’s 2021

Biotech Damian Garde

STAT Plus: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

The Readout Meghana Keshavan

STAT Plus: GSK pill works in uncomplicated gonorrhea

Biotech Andrew Joseph

STAT Plus: Viking Therapeutics obesity drug hits target in key study, raising hopes for a competitor to existing medicines

The Readout Damian Garde

STAT Plus: The FDA isn’t afraid to yank a disappointing drug